What is the Growth Projection for the Global Eylea Market?
The Eylea market size has seen consistent growth, escalating from $8.09 billion in 2024 to an expected $8.49 billion in 2025, reporting a compound annual growth rate (CAGR) of 4.9%. The historic growth can be tied to the prevalence of diabetic macular edema (DME), clinical efficacy and safety profiles, competitive anti-VEGF therapies, approval for various retinal conditions, and a shift towards intravitreal injections. Furthermore, the Eylea market size is forecasted to grow steadily to $10.75 billion in 2029 at a CAGR of 6.1%. Growth in the forecast period will be driven by emerging therapeutic indications, the introduction of biosimilar competition, increased awareness and diagnosis, real-world evidence and post-market studies, and patient preference for less frequent injections.
Get Your Free Sample of The Global Eylea Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9155&type=smp
What is Driving the Surge in the Eylea Market?
Significantly, the increasing prevalence of ocular diseases is expected to drive the Eylea market forward. Ocular diseases are those that interfere with the eye’s proper functioning, negatively affecting vision and clarity. Eylea is used to treat such diseases, including wet age-related macular degeneration (AMD) and glaucoma, which cause damage to the retina or macula and affect vision.
What are the Main Segments within the Global Eylea Market?
* By Product: Prefilled Syringe Package, Vial Package
* By Disorder: Wet Age-Related Macular Degeneration (AMD), Diabetic Retinopathy, Other Disorders
* By Application: Hospitals, Retail Pharmacy, Other Applications
Order your report now for swift delivery:
https://www.thebusinessresearchcompany.com/report/eylea-global-market-report
Who are the Dominant Players in the Eylea Market?
The most prominent companies in the Eylea market comprise Regeneron Pharmaceuticals Inc., Bayer AG, Novartis AG, Roche Holding AG, Pfizer Inc., Amgen Inc., Sanofi S.A., AbbVie Inc., Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., GlaxoSmithKline plc, Biogen Inc., Alcon Inc., Johnson & Johnson, Eli Lilly and Company, Genentech Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Samsung Bioepis Co. Ltd., Lupin Limited, Sun Pharmaceutical Industries Ltd., Zydus Cadila, Torrent Pharmaceuticals Ltd., Dr. Reddy’s Laboratories Ltd., Cipla Ltd., Amneal Pharmaceuticals LLC, and Apotex Inc.
What Innovations are Impacting the Eylea Market?
Research and developments are gaining traction in the Eylea market. For instance, in August 2023, Regeneron Pharmaceuticals, Inc, a global biotechnology company, received US FDA approval for Eylea HD (aflibercept) injection 8 mg to address patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR).
Which Regions are Spearheading the Eylea Market Growth?
North America held the largest share in the Eylea market in 2024. However, Asia-Pacific is slated to be the fastest-growing region in the market. Other regions covered in the report include Western Europe, Eastern Europe, South America, Middle East, and Africa.
Eylea Market Definition: What Does The Eylea Market Report 2025 Offer?
Eylea is a type of drug injected into the eye that helps slow vision loss and certain other diseases by blocking the leaking and growth of fluid from abnormal blood vessels from the back of the eye. It is used to treat age-related macular degeneration (AMD). The Eylea Market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9155
About The Business Research Company
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has established a reputation for delivering comprehensive, data-rich research and insights. With 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, we aim to provide the information you need to stay ahead.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
